Thursday, May 19, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

SARS-CoV-2 breakthrough infections elicit potent neutralizing antibody responses

by Medical Finance
in Coronavirus
Scientists discover antibody that inhibits a broad range of sarbecoviruses
9
SHARES
102
VIEWS
Share on FacebookShare on Twitter

Jan 20 2022

A recent study looked at the strength, durability and breadth of neutralizing antibody responses generated by breakthrough infections in individuals vaccinated against SARS-CoV2.

The findings are published this week in Cell, one of the scientific journals of Cell Press.  Alexandra Walls and David Veesler in the Department of Biochemistry at the University of Washington in Seattle led the project.

Characteristics of the Delta and Omicron coronavirus variants of concern include enhanced transmissibility and immune evasion even in non-immunologically naïve individuals, compared to the ancestral pandemic coronavirus.

These characteristics, and the waning of immunity from vaccines, have led to breakthrough infections in vaccinated individuals.  For the most part, otherwise healthy people who are vaccinated against the SARS-CoV-2 usually do not have severe symptoms if they do end up contracting the virus.

The researchers wanted to understand what effect catching the virus after being vaccinated has on neutralizing antibodies, and to see how durable and broad these responses are. Their hope is that advancing such knowledge will help guide vaccination policies and pandemic mitigation strategies.

Through their project the researchers learned that the degree of antibody response depended on whether a person has had one, two, three, or four exposures to the spike protein through infection, vaccination, or a mixture of the two. The scientists also checked antibody responses in groups of individuals who had been vaccinated after having COVID-19, those who were previously vaccinated and experienced a breakthrough infection, those who were vaccinated only, and those who were boosted and therefore vaccinated three times.

Among their study subjects, those who had completed a three-vaccination protocol, and those who had been vaccinated after recovering from COVID-19, and those with a breakthrough infection after vaccination launched almost comparable neutralizing antibody responses, in terms of magnitude and breadth.  Their serum binding and antibody neutralizing responses to the spike protein in the current pandemic coronavirus variants were much more potent and lasting than those generated by people who had received only two doses of COVID-19 vaccine or who had a previous infection not followed by vaccination.

This observation suggested that the increased number of exposures to SARS-CoV-2 antigens, either through infection and vaccination or triple vaccination, enhanced the quality of antibody responses.

The researchers also looked at how broad the elicited antibodies could be. They investigated neutralization of the divergent Omicron SARS-CoV-2 variant of concern, currently responsible for the majority of cases in the United States. Their findings showed that boosted individuals (or those that have a mixture of infection and double vaccination) have neutralizing antibodies at similar levels to subjects vaccinated twice against the original ancestral strain. This suggests a large amount of immune evasion, but that vaccine boosters can help close the neutralizing antibody gap caused by Omicron.

Looking outside of the SARS-CoV-2 family shows a similar pattern, where repeated and multiple exposures improves the otherwise weak neutralizing antibody response to SARS-CoV. Finally, the authors did not identify improvements in antibody binding to common cold causing coronavirus spike proteins like OC43 or HKU1. This suggests that repeated SARS-CoV-2 exposure does not improve spike reactivity to more divergent coronaviruses. These findings support the development of broader sarbecovirus or coronavirus vaccines to be prepared in the event of a future spillover event.

The study groups consisted of about 15 people, from the Hospitalized or Ambulatory Adults with Respiratory Viral Infections, or HAARVI, project at the UW in Seattle. HAARVI, led by UW Medicine infectious disease physician Helen Chu, looks at recovered COVID-19 patients to study immune responses over time, to understand the long-term consequences of the infection, and to compare immune responses from vaccines and natural infections.  

The study was supported by grants from the National Institutes of Allergy and Infectious Diseases (DP1AI158186 and HHSN272201700059C), a Pew Medical Scholars Award, an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund, Fast Grants, and the Melinda & Bill Gates Foundation (OPP1156262).  Veesler is an investigator of the Howard Hughes Medical Institute.

Researchers from the Department of Medicine and the Department of Laboratory Medicine and Pathology at the UW School of Medicine, and from Humabs Biomed SA, a subsidiary of Vir Biotechnology, also helped conduct the study.

Source:

Journal reference:

Walls, A.C., et al. (2022) SARS-CoV-2 breakthrough infections elicit potent, broad and durable neutralizing antibody responses. Cell. doi.org/10.1016/j.cell.2022.01.011.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains. Image Credit: LuXiFeR Bowlo/Shutterstock

Study provides a potent biparatopic antibody against all SARS-CoV-2 variants of concern

by Medical Finance
May 19, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the potent neutralization of severe acute respiratory syndrome coronavirus...

Study: Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects Macaques from infection. Image Credit: Kateryna Kon/Shutterstock

Study suggests synthetic SARS-CoV-2 S glycoprotein coated lipid vesicles are an effective vaccine candidate

by Medical Finance
May 19, 2022
0

In a study published in the latest issue of the journal Cell Reports Medicine, a team of researchers developed a vaccine...

Study: Long-term detection of SARS-CoV-2 antibodies after infection and risk of re-infection. Image Credit: Corona Borealis Studio/Shutterstock

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

by Medical Finance
May 19, 2022
0

In a new preproof study published in the latest issue of the International Journal of Infectious Diseases, a team of...

Study: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Image Credit: BaLL LunLa/Shutterstock

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

by Medical Finance
May 19, 2022
0

In a recent study posted to the journal Cell, researchers evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination-induced cross-recognition...

Study: COVID-19 and its clinical severity are associated with alterations of plasma sphingolipids and enzyme activities of sphingomyelinase and ceramidase. Image Credit: alessandro guerriero/Shutterstock

Alterations of sphingolipids and their metabolizing enzymes in hospitalized or convalescent COVID-19 patients

by Medical Finance
May 19, 2022
0

In a study posted to the medRxiv* preprint server, an interdisciplinary team of researchers from Europe analyzed the alterations...

Study: No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2. Image Credit: Corona Borealis Studio / Shutterstock

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

by Medical Finance
May 19, 2022
0

Every time a new variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerges, the question arises, “is it...

Next Post
TetraScience announces 300% ARR growth and 2021 achievements; prepares for next phase of growth

Origin, evolution and ecological relationships of yeasts

Study: SARS-CoV-2 Omicron-specific mRNA vaccine induces potent and broad antibody responses in vivo. Image Credit: angellodeco / Shutterstock.com

Researchers develop novel anti-SARS-CoV-2 Omicron vaccine candidate

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • antibody in pink and red background selective focus 3d art Mirror Images A1 71b890c58eb74b42a6490cfe1b003dce 620x480
    Enzyme discovery offers new way to regulate cell death process for inflammatory diseases
  • Study: Safety, tolerability, and viral kinetics during SARS-CoV-2 human challenge. Image Credit: Jirsack / Shutterstock.com
    SARS-CoV-2 human challenge study offers novel insights into viral kinetics
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply